Loading Events

Sensei Biotherapeutics Investor Webcast to Discuss Clinical Data from Phase 1 Dose Escalation Study of SNS-101 at the 2024 ASCO Annual Meeting

DATE: June 3, 2024

About The Event

Join Sensei Biotherapeutics for an investor webcast featuring Dr. Shiraj Sen, MD, PhD, Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas, who will join company management to discuss clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Dr. Sen is an investigator on the ongoing Phase 1/2 trial and lead author of the SNS-101 poster being presented on June 1, 2024 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

A live question and answer session will follow the formal presentation.